GSK Stock Recent News

GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.

Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

British pharmaceutical giant GSK said on Wednesday it will cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States, following similar moves by two of its rivals.

Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.

In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the latest findings of a late-stage trial by GSK seeking to expand the use of the treatment.

Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.